Take Homes in CAR T-cell Therapy

Take Homes in CAR T-cell Therapy

Source:

Locke F, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.

Kamdar M, et al. Abstract 91. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.


Disclosures: Sasine reports consulting for Kite Pharma and on being on the speaker’s bureau for Kite Pharma and Bristol Myers Squibb.
December 17, 2021
1 min watch
Save

VIDEO: New data on allogeneic CAR T-cells

Source:

Locke F, et al. Abstract 2. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.

Kamdar M, et al. Abstract 91. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.


Disclosures: Sasine reports consulting for Kite Pharma and on being on the speaker’s bureau for Kite Pharma and Bristol Myers Squibb.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

In this video, Joshua Sasine, MD, PhD, assistant professor of medicine hematology and cellular therapy at Samuel Oschin Cancer Center Regenerative Medicine Institute, discusses new allogeneic chimeric antigen receptor T-cell therapy data.

The important data, which was presented at ASH, came in terms of the durability of the allogeneic CAR T cells, which Sasine said did not seem to be as durable as autologous CAR T cells.

"I think this might change the way we use these in the real-world setting, perhaps using them after auto CAR-T or in those patients who have auto CAR-T manufacturing failure or those who have aggressive disease," he said.